{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:06:57Z","timestamp":1792530417650,"version":"4.5.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/iae.0b013e3182a0e446","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T18:06:26Z","timestamp":1375293986000},"page":"490-496","source":"Crossref","is-referenced-by-count":21,"title":["TREATMENT OF PERSISTENT SEROUS RETINAL DETACHMENT IN VOGT\u2013KOYANAGI\u2013HARADA SYNDROME WITH INTRAVITREAL BEVACIZUMAB DURING THE SYSTEMIC STEROID TREATMENT"],"prefix":"10.1097","volume":"34","author":[{"given":"Michele","family":"Reibaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresio","family":"Avitabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio G.","family":"Uva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario D.","family":"Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Cennamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola D.","family":"Noci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210130","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/ICU.0b013e32833eb78c","article-title":"Vogt-Koyanagi-Harada disease: diagnosis and treatments update.","volume":"21","author":"Bordaberry","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"key":"R2-9-20210130","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9394(01)00925-4","article-title":". Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.","volume":"131","author":"Read","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R3-9-20210130","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ajo.2008.08.034","article-title":". Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: considerations on the different disease categories.","volume":"147","author":"da Silva","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R4-9-20210130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/IAE.0b013e3181c5970d","article-title":"Retinal pigment epithelial changes in chronic Vogt-Koyanagi-Harada disease: fundus autofluorescence and spectral domain-optical coherence tomography findings.","volume":"30","author":"Vasconcelos-Santos","year":"2010","journal-title":"Retina"},{"key":"R5-9-20210130","first-page":"157","article-title":". Sindrome de Vogt-Koyanagi-Harada, actualizacion.","volume":"22","author":"Diaz-Llopis","year":"2004","journal-title":"Studium Ophthalologicum"},{"key":"R6-9-20210130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09273940500536766","article-title":"Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.","volume":"14","author":"Paredes","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"key":"R7-9-20210130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00417-010-1477-8","article-title":"Intravitreal bevacizumab injection for persistent serous retinal detachment associated with Vogt-Koyanagi-Harada disease.","volume":"249","author":"Park","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R8-9-20210130","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1177\/112067210701700611","article-title":". Increased vascular endothelial growth factor levels in aqueous humor and serum of patients with quiescent uveitis.","volume":"17","author":"Paroli","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"R9-9-20210130","doi-asserted-by":"crossref","first-page":"21036","DOI":"10.1074\/jbc.M109.016766","article-title":"Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability.","volume":"284","author":"Murakami","year":"2009","journal-title":"J Biol Chem"},{"key":"R10-9-20210130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-2003-40465","article-title":". Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF).","volume":"111","author":"Nicoletti","year":"2003","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R11-9-20210130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/IAE.0b013e3181bcf0b4","article-title":"Intravitreal bevacizumab injection for central serous chorioretinopathy.","volume":"30","author":"Lim","year":"2010","journal-title":"Retina"},{"key":"R12-9-20210130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/112067210901900415","article-title":". Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy.","volume":"19","author":"Schaal","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"R13-9-20210130","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0002-9394(01)00830-3","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.","volume":"131","author":"Jabs","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R14-9-20210130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3341\/kjo.2009.23.2.74","article-title":". Edema of the photoreceptor layer in Vogt-Koyanagi-Harada disease observed using high-resolution optical coherence tomography.","volume":"23","author":"Lee","year":"2009","journal-title":"Korean J Ophthalmol"},{"key":"R15-9-20210130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ajo.2006.02.049","article-title":". Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.","volume":"142","author":"Read","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R16-9-20210130","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/112067210901900126","article-title":". Low-fluence photodynamic therapy in longstanding chronic central serous chorioretinopathy with foveal and gravitational atrophy.","volume":"19","author":"Reibaldi","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"R17-9-20210130","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1055\/s-2002-30660","article-title":". Corticosteroid-induced central serous chorioretinopathy in patients with ocular inflammatory disorders.","volume":"219","author":"Schalenbourg","year":"2002","journal-title":"Klin Monbl Augenheilkd"},{"key":"R18-9-20210130","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3899\/jrheum.091230","article-title":"The dilemma of central serous retinopathy, a corticosteroid-induced complication, in patients with ocular inflammatory disease.","volume":"37","author":"Gupta","year":"2010","journal-title":"J Rheumatol"},{"key":"R19-9-20210130","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/eye.2010.130","article-title":"Central serous chorioretinopathy: an update on pathogenesis and treatment.","volume":"24","author":"Gemenetzi","year":"2010","journal-title":"Eye (Lond)"},{"key":"R20-9-20210130","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0161-6420(97)30262-0","article-title":"Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up.","volume":"104","author":"Burumcek","year":"1997","journal-title":"Ophthalmology"},{"key":"R21-9-20210130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00006982-200306000-00002","article-title":". Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study.","volume":"23","author":"Yannuzzi","year":"2003","journal-title":"Retina"},{"key":"R22-9-20210130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000314709","article-title":". Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.","volume":"225","author":"Inoue","year":"2011","journal-title":"Ophthalmologica"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0b013e3182a0e446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:46:47Z","timestamp":1620953207000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201403000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e3182a0e446","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}